These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21217359)

  • 21. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
    Brites FD; Verona J; Schreier LE; Fruchart JC; Castro GR; Wikinski RL
    Arch Med Res; 2004; 35(3):235-40. PubMed ID: 15163466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triglycerides and endothelial function: molecular biology to clinical perspective.
    Kajikawa M; Higashi Y
    Curr Opin Lipidol; 2019 Oct; 30(5):364-369. PubMed ID: 31348023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
    Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile.
    Blackburn P; Lemieux I; Alméras N; Bergeron J; Côté M; Tremblay A; Lamarche B; Després JP
    Metabolism; 2009 Aug; 58(8):1123-30. PubMed ID: 19481769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis.
    Loomba RS; Arora R
    Am J Ther; 2010; 17(6):e182-8. PubMed ID: 20535009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of Omacor in severe hypertriglyceridemia.
    Harris WS; Ginsberg HN; Arunakul N; Shachter NS; Windsor SL; Adams M; Berglund L; Osmundsen K
    J Cardiovasc Risk; 1997; 4(5-6):385-91. PubMed ID: 9865671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates.
    Cicero AF; Derosa G; Miconi A; Laghi L; Nascetti S; Gaddi A
    Biomed Pharmacother; 2005 Jul; 59(6):312-7. PubMed ID: 15932792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between triglyceride levels and cardiovascular disease in patients with acute pancreatitis.
    Copeland LA; Swendsen CS; Sears DM; MacCarthy AA; McNeal CJ
    PLoS One; 2018; 13(1):e0179998. PubMed ID: 29381696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fibrates: their prescription must be restricted].
    Béliard-Lasserre S
    Rev Prat; 2015 Dec; 65(10):1243-4. PubMed ID: 26979011
    [No Abstract]   [Full Text] [Related]  

  • 32. Characterization of hypertriglyceridemia and response to treatment with insulin in llamas and alpacas: 31 cases (1995-2005).
    Waitt LH; Cebra CK
    J Am Vet Med Assoc; 2008 May; 232(9):1362-7. PubMed ID: 18447783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current perspectives on the management of hypertriglyceridemia.
    Miller M
    Am Heart J; 2000 Aug; 140(2):232-40. PubMed ID: 10925336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatty acid-binding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects.
    Pishva H; Mahboob SA; Mehdipour P; Eshraghian MR; Mohammadi-Asl J; Hosseini S; Karimi F
    Nutrition; 2010; 26(11-12):1117-21. PubMed ID: 20080390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long-term safety and efficacy of fibrates in patients with hypertriglyceridemia: Real-life data from a lipid clinic cohort.
    Zambon A
    Turk Kardiyol Dern Ars; 2020 Jun; 48(4):357-358. PubMed ID: 32519990
    [No Abstract]   [Full Text] [Related]  

  • 36. Patient information page from The Hormone Foundations. Patient guide to the assessment and treatment of hypertriglyceridemia (high triglycerides).
    Berglund L; Brunzell J; Sacks FM
    J Clin Endocrinol Metab; 2012 Sep; 97(9):31A-32A. PubMed ID: 22962678
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypertriglyceridemia and low HDL: therapeutic considerations.
    Larsen ML
    Curr Opin Lipidol; 1994 Feb; 5(1):42-7. PubMed ID: 15559030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plasmapheresis in hypertriglyceridemic acute pancreatitis].
    Pérez-Martínez D; Martínez-Quintana ME
    Med Intensiva; 2015; 39(6):387-8. PubMed ID: 25499461
    [No Abstract]   [Full Text] [Related]  

  • 39. [Fibrates, clinical use and their effects].
    Tada N
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():614-20. PubMed ID: 21766670
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic Variations, Triglycerides, and Atherosclerotic Disease.
    Tada H; Kawashiri MA
    J Atheroscler Thromb; 2019 Feb; 26(2):128-131. PubMed ID: 30078832
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.